See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Muu" projekt AR12171
AR12171 "Development of Trk antagonists as drug candidates for the treatment of neuropathic pain (1.09.2012−31.08.2015)", Tõnis Timmusk, Tallinna Tehnikaülikool, Tallinna Tehnikaülikool, Matemaatika-loodusteaduskond, Geenitehnoloogia instituut, Molekulaarbioloogia õppetool.
AR12171
Development of Trk antagonists as drug candidates for the treatment of neuropathic pain
Development of Trk antagonists as drug candidates for the treatment of neuropathic pain
Development of Trk antagonists as drug candidates for the treatment of neuropathic pain
1.09.2012
31.08.2015
Teadus- ja arendusprojekt
Muu
ValdkondAlamvaldkondCERCS erialaFrascati Manual’i erialaProtsent
3. Terviseuuringud3.7. Kliiniline meditsiinB640 Neuroloogia, neuropsühholoogia, neurofüsioloogia 3.2. Kliiniline meditsiin (anestesioloogia, pediaatria, sünnitusabi ja günekoloogia, sisehaigused, kirurgia, stomatoloogia, neuroloogia, psühhiaatria, radioloogia, terapeutika, otorinolarüngoloogia, oftalmoloogia)50,0
3. Terviseuuringud3.3. FarmaatsiaB740 Farmakoloogia, farmakognoosia, farmaatsia, toksikoloogia 3.1. Biomeditsiin (anatoomia, tsütoloogia, füsioloogia, geneetika, farmaatsia, farmakoloogia, kliiniline keemia, kliiniline mikrobioloogia, patoloogia)50,0
AsutusRiikTüüp
SA Archimedes
PerioodSumma
01.09.2012−31.08.2015226 100,00 EUR
226 100,00 EUR
National R&D program „Biotechnology“

The aim of the project is to identify and characterize novel low molecular weight antagonists of TrkA and TrkB receptors, as drug candidates for the treatment of pain, using methods of computer chemistry, organic synthesis of the compounds, molecular and cell biology, toxicology and animal models of neuropathic pain. As such the current research aim meets the fourth goal of sub-measure - early stage technologies of drug development.
The aim of the project is to identify and characterize novel low molecular weight antagonists of TrkA and TrkB receptors, as drug candidates for the treatment of pain, using methods of computer chemistry, organic synthesis of the compounds, molecular and cell biology, toxicology and animal models of neuropathic pain. As such the current research aim meets the fourth goal of sub-measure - early stage technologies of drug development.
TegevusProtsent
Alusuuring80,0
Rakendusuuring20,0